Shares of Lyell Immunopharma, Inc. (LYEL) are up more than 13% Monday morning at $8.60.
The company today presented first-in-human Phase 1 study design of its ROR1-targeted CAR T-cell therapy LYL797 for the treatment of solid tumors, at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.
"This first-in-human Phase 1 trial is designed to provide important data on the potential of Lyell's innovative reprogramming technologies to endow T cells with durable anti-tumor functionality," stated Tina Albertson, chief medical officer of Lyell.
LYEL has been trading in the range of $3.57-$17.75in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.